Based on these data, chemo-immunotherapy (CIT) has been established as the standard of care in the first-line treatment of non-oncogene addicted metastatic NSCLC for patients with good performance status, any histology, and any PD-L1 expression [39]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.